This study provides valuable insights into the prevalence of EGFR mutation in our setting, which is similar to those reported in the literature for Latin American and European series, as well as clinical characteristics, treatment and outcomes in stage IV lung cancer patients. This evidence concerns the gene EGFR and lung carcinoma.